Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Companies	$4.79 +4.2%	$5.79	$3.96 ▼ $9.85	$1.73B	0.34	2.63 million shs	3.20 million shs
HRMY Harmony Biosciences	$35.65 +4.7%	$31.38	$26.47 ▼ $41.61	$2.05B	0.82	588,814 shs	958,561 shs
MIRM Mirum Pharmaceuticals	$45.57 +2.9%	$42.82	$23.83 ▼ $54.23	$2.25B	0.95	525,290 shs	385,948 shs
SBTX Silverback Therapeutics	$13.44 -0.4%	$13.10	$2.80 ▼ $8.97	$484.62M	0.6	337,931 shs	1.09 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Companies	0.00%	-15.97%	+5.20%	-27.95%	-33.87%
HRMY Harmony Biosciences	0.00%	+12.30%	+16.73%	-10.37%	+12.97%
MIRM Mirum Pharmaceuticals	0.00%	+1.33%	+11.85%	-12.27%	+78.80%
SBTX Silverback Therapeutics	0.00%	-7.05%	+1.51%	+12.75%	+53.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHC Bausch Health Companies	4.2754 of 5 stars	2.9	3.0	0.0	4.0	2.7	1.7	1.9
HRMY Harmony Biosciences	4.9158 of 5 stars	4.5	3.0	0.0	0.0	3.9	3.3	4.4
MIRM Mirum Pharmaceuticals	4.0966 of 5 stars	3.5	1.0	0.0	4.2	3.4	2.5	0.6
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Companies	1.86	Reduce	$7.42	55.00% Upside
HRMY Harmony Biosciences	3.00	Buy	$52.33	46.80% Upside
MIRM Mirum Pharmaceuticals	3.09	Buy	$59.00	29.47% Upside
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SBTX, BHC, HRMY, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$74.00 ➝ $76.00
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
5/2/2025	BHC Bausch Health Companies	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$8.50 ➝ $10.00
4/28/2025	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00
4/8/2025	HRMY Harmony Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
4/8/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
4/7/2025	BHC Bausch Health Companies	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform	$9.00 ➝ $8.50
3/18/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $44.00
2/28/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$66.00 ➝ $72.00
2/27/2025	HRMY Harmony Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $70.00
2/27/2025	MIRM Mirum Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$50.00 ➝ $55.00

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Companies	$9.73B	0.18	$5.09 per share	0.94	($0.89) per share	-5.38
HRMY Harmony Biosciences	$744.85M	2.75	$2.66 per share	13.38	$7.97 per share	4.47
MIRM Mirum Pharmaceuticals	$379.25M	5.94	N/A	N/A	$5.33 per share	8.55
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Companies	-$46M	-$0.11	N/A	1.03	0.37	-0.48%	-577.82%	5.24%	7/30/2025 (Estimated)
HRMY Harmony Biosciences	$128.85M	$2.62	16.90	11.46	0.47	17.98%	23.16%	14.24%	N/A
MIRM Mirum Pharmaceuticals	-$163.41M	-$1.61	N/A	N/A	N/A	-31.69%	-41.22%	-14.81%	5/14/2025 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	∞	N/A	N/A	-29.62%	-28.20%	N/A

Latest SBTX, BHC, HRMY, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
2/26/2025	Q4 2024	MIRM Mirum Pharmaceuticals	-$0.27	-$0.49	-$0.22	-$0.49	$96.64 million	$99.41 million
2/25/2025	Q4 2024	HRMY Harmony Biosciences	$0.74	$0.85	+$0.11	$0.85	$201.25 million	$201.30 million
2/19/2025	Q4 2024	BHC Bausch Health Companies	$1.65	$1.21	-$0.44	$0.25	$2.51 billion	$2.56 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Companies	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Companies	N/A	0.86	0.62
HRMY Harmony Biosciences	0.28	3.24	3.20
MIRM Mirum Pharmaceuticals	1.33	3.34	3.15
SBTX Silverback Therapeutics	N/A	67.87	67.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Companies	78.65%
HRMY Harmony Biosciences	86.23%
MIRM Mirum Pharmaceuticals	N/A
SBTX Silverback Therapeutics	74.89%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Companies	8.05%
HRMY Harmony Biosciences	23.60%
MIRM Mirum Pharmaceuticals	14.36%
SBTX Silverback Therapeutics	34.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Companies	19,900	362.11 million	338.06 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	39.47 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.45 million	37.03 million	Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable

SBTX, BHC, HRMY, and MIRM Headlines

Recent News About These Companies

Silverback Therapeutics (NASDAQ:SBTX) Stock Price Down 3.8% - Here's Why

May 12 at 4:17 AM | marketbeat.com

Silverback Therapeutics (NASDAQ:SBTX) Shares Down 0.7% - Here's Why

April 20, 2025 | marketbeat.com

Meet the Silverback, the Leader of the Troop

October 17, 2024 | pbs.org

10 Fun Facts About Mountain Gorillas

September 18, 2024 | nationalgeographic.com

CapstanTx secures $165 million to deliver precise in vivo cell engineering

July 28, 2024 | pharmaphorum.com

ARS Pharmaceuticals Inc (SPRY)

May 11, 2023 | uk.investing.com

Wild Isles

March 12, 2023 | wwf.org.uk

A look back at RNA Therapeutics – day one

February 24, 2023 | pharmaphorum.com

SPRY ARS Pharmaceuticals, Inc.

January 24, 2023 | seekingalpha.com

ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger

November 22, 2022 | 247wallst.com

Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics

November 18, 2022 | nasdaq.com

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

November 10, 2022 | finance.yahoo.com

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

November 8, 2022 | finance.yahoo.com

Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions

October 28, 2022 | markets.businessinsider.com

FDA accepts ARS Pharma’s NDA for Neffy

October 24, 2022 | thepharmaletter.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI

October 23, 2022 | kentuckytoday.com

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

October 21, 2022 | finance.yahoo.com

Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?

October 19, 2022 | aaii.com

SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN

October 12, 2022 | bakersfield.com

INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT

September 17, 2022 | markets.businessinsider.com

SBTX Silverback Therapeutics, Inc.

September 15, 2022 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX, BHC, HRMY, and MIRM Company Descriptions

Bausch Health Companies NYSE:BHC

$4.78 +0.20 (+4.25%)

Closing price 03:59 PM Eastern

Extended Trading

$4.82 +0.03 (+0.63%)

As of 06:46 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Harmony Biosciences NASDAQ:HRMY

$35.65 +1.60 (+4.70%)

Closing price 04:00 PM Eastern

Extended Trading

$35.16 -0.48 (-1.36%)

As of 04:38 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Mirum Pharmaceuticals NASDAQ:MIRM

$45.57 +1.30 (+2.94%)

Closing price 04:00 PM Eastern

Extended Trading

$45.56 -0.01 (-0.01%)

As of 04:05 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Silverback Therapeutics NASDAQ:SBTX

$13.44 -0.05 (-0.37%)

As of 05/9/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time